-+ 0.00%
-+ 0.00%
-+ 0.00%

LEADS BIOLABS' OPAMTISTOMIG (PD-L1/4-1BB BISPECIFIC ANTIBODY) ADVANCES TO EXPANSION STAGE IN PHASE II FIRST-LINE GASTRIC CANCER STUDY

Reuters·10/20/2026 10:18:11

Please log in to view news